TY - JOUR
T1 - Effect of antidepressant treatment on plasma levels of neuroinflammation-associated molecules in patients with somatic symptom disorder with predominant pain around the orofacial region
AU - Miyauchi, Tomoya
AU - Tokura, Tatsuya
AU - Kimura, Hiroyuki
AU - Ito, Mikiko
AU - Umemura, Eri
AU - Sato (Boku), Aiji
AU - Nagashima, Wataru
AU - Tonoike, Takashi
AU - Yamamoto, Yasuko
AU - Saito, Kuniaki
AU - Kurita, Kenichi
AU - Ozaki, Norio
N1 - Funding Information:
Dr. Miyauchi reports personal fees from IGAKU‐SHOIN, CHUGAI‐ IGAKUSHA, Japan Medical Journal, KINPODO, NANZANDO, Tsumura, and Pfizer, outside the submitted work. Dr. Tokura reports grants from a governmental grant in aid for young scientists (B, No. 26860923) from the Japanese Society for the Promotion of Science, and a governmental grant in aid for scientific research (C, No. 17K10325) from the Japanese Ministry of Education, Culture, Sports, Science and Technology, during the conduct of the study; personal fees from Otsuka Pharmaceutical, Eli Lilly, Meiji Seika Pharma, Mochida Pharmaceutical, Zen‐Nihon Byouin Shuppankai, Medical Review, Seishin Kango Shuppan, and World Planning, outside the submitted work. Dr. Kimura reports grants from a governmental grant in aid for scientific research (C, No. 17K10325) from the Japanese Ministry of Education, Culture, Sports, Science and Technology, and a governmental grant in aid for scientific research (C, No. 24591703) from the Japanese Ministry of Education, Culture, Sports, Science and Technology, during the conduct of the study. Dr. Ito reports personal fees from Nagasue shoten, outside the submitted work. Dr. Nagashima reports personal fees from MSD, outside the submitted work. Dr. Saito reports grants from A&T Corporation, FUJIFILM Wako Pure Chemical Corporation, Marukome, Tsuji Oil & Mills, Nisshin Seifun Group, Matsutani Chemical Industry, and Morinaga Milk Industry, outside the submitted work. Dr. Kurita reports personal fees from Nagasue shoten, outside the submitted work. Dr. Ozaki reports grants from Japan Agency for Medical Research and development (AMED) (No. JP18dk0307075 & No. JP 18dk0307081), during the conduct of the study; grants and personal fees from Astellas pharma, MSD, Otsuka Pharmaceutical, Takeda Pharmaceutical, Sumitomo Dainippon Pharma, Novartis, Pfizer, and KAITEKI, outside the submitted work; grants from Eisai, Mitsubishi Tanabe Pharma, Tsumura, and Nihon Medi‐Physics, outside the submitted work; personal fees from Ono pharmaceutical, Kyowa Hakko Kirin, Eli Lilly, Meiji Seika Pharma, Mochida Pharmaceutical, Janssen Pharmaceutical, and Taisho Pharmaceutical, outside the submitted work.
Funding Information:
Japan Agency for Medical Research and Development, Grant/Award Numbers: JP18dk0307075 and JP18dk0307081; Japanese Ministry of Education, Culture, Sports, Science and Technology, Grant/Award Number: C, No. 17K10325 C, No. 24591703; Japanese Society for the Promotion of Science, Grant/Award Number: B, No. 26860923
Funding Information:
This research was supported by the Japan Agency for Medical Research and Development (AMED) under Grant No. JP18dk0307075 and No. JP18dk0307081, a governmental grant in aid for scientific research (C, No. 24591703) from the Japanese Ministry of Education, Culture, Sports, Science and Technology, a governmental grant in aid for young scientists (B, No. 26860923) from the Japanese Society for the Promotion of Science, and a governmental grant in aid for scientific research (C, No. 17K10325) from the Japanese Ministry of Education, Culture, Sports, Science and Technology. We thank Dr. Keizo Yoshida (Health Care Promotion Division, DENSO Corporation, Kariya, Aichi) for power analysis. We thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.
Publisher Copyright:
© 2019 John Wiley & Sons, Ltd.
PY - 2019/7
Y1 - 2019/7
N2 - Objective: Burning mouth syndrome (BMS) and atypical odontalgia (AO) are examples of somatic symptom disorders with predominant pain around the orofacial region. Neuroinflammation is thought to play a role in the mechanisms, but few studies have been conducted. We aimed to better understand the role of neuroinflammation in the pathophysiology and treatment of BMS/AO. Methods: Plasma levels of 28 neuroinflammation-related molecules were determined in 44 controls and 48 BMS/AO patients both pretreatment and 12-week post-treatment with duloxetine. Results: Baseline plasma levels of interleukin (IL)-1β (p <.0001), IL-1 receptor antagonist (p <.001), IL-6 (p <.0001), macrophage inflammatory protein-1β (p <.0001), and platelet-derived growth factor-bb (.04) were significantly higher in patients than in controls. Plasma levels of granulocyte macrophage colony stimulating factor were significantly higher in patients than in controls (p <.001) and decreased with treatment (.009). Plasma levels of eotaxin, monocyte chemoattractant protein-1, and vascular endothelial growth factor decreased significantly with treatment (p <.001,.022, and.029, respectively). Conclusions: Inflammatory mechanisms may be involved in the pathophysiology and/or treatment response of somatic symptom disorders with predominant pain around the orofacial region.
AB - Objective: Burning mouth syndrome (BMS) and atypical odontalgia (AO) are examples of somatic symptom disorders with predominant pain around the orofacial region. Neuroinflammation is thought to play a role in the mechanisms, but few studies have been conducted. We aimed to better understand the role of neuroinflammation in the pathophysiology and treatment of BMS/AO. Methods: Plasma levels of 28 neuroinflammation-related molecules were determined in 44 controls and 48 BMS/AO patients both pretreatment and 12-week post-treatment with duloxetine. Results: Baseline plasma levels of interleukin (IL)-1β (p <.0001), IL-1 receptor antagonist (p <.001), IL-6 (p <.0001), macrophage inflammatory protein-1β (p <.0001), and platelet-derived growth factor-bb (.04) were significantly higher in patients than in controls. Plasma levels of granulocyte macrophage colony stimulating factor were significantly higher in patients than in controls (p <.001) and decreased with treatment (.009). Plasma levels of eotaxin, monocyte chemoattractant protein-1, and vascular endothelial growth factor decreased significantly with treatment (p <.001,.022, and.029, respectively). Conclusions: Inflammatory mechanisms may be involved in the pathophysiology and/or treatment response of somatic symptom disorders with predominant pain around the orofacial region.
UR - http://www.scopus.com/inward/record.url?scp=85066912556&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066912556&partnerID=8YFLogxK
U2 - 10.1002/hup.2698
DO - 10.1002/hup.2698
M3 - Article
C2 - 31125145
AN - SCOPUS:85066912556
VL - 34
JO - Human Psychopharmacology
JF - Human Psychopharmacology
SN - 0885-6222
IS - 4
M1 - e2698
ER -